Biotech Weekly Recap
Welcome to this week's Evergrowth Biotech Weekly Recap, where we dive into the latest updates and developments in the biotech sector. 🌟
In this episode, Dr. Harvey CH and Christina Bear discuss emerging trends, innovative drugs, and key advancements from both large-cap and small-cap biotech companies. This week’s highlights include:
Viking Therapeutics’ promising obesity medication advancements
Exelixis’ regulatory progress for pancreatic cancer treatments
Updates on AMG’s combination therapy for colorectal cancer
Insights from the upcoming JP Morgan Healthcare Conference
Disclaimer: This video is for informational purposes only and does not constitute investment advice. Always conduct your own research or consult with a financial advisor before making investment decisions.
📧 Contact us for a free consultation: [email protected]
📱 Scan the QR code in the video for more details.
Stay informed about the biotech sector and make educated investment decisions. Don’t forget to like, comment, and subscribe for weekly updates!
#BiotechNews #HealthcareInvesting #PharmaceuticalUpdates #EmergingBiotech #StockMarketAnalysis #JPHealthcareConference #GeneTherapy #ObesityMedications #CancerResearch #BiotechInnovation
▶ SCHEDULE A CALL WITH DR. TRAN:
https://calendly.com/drharveytran/eve...
▶ CONNECT WITH US:
Website: https://evergrowthinvest.com/
Email: [email protected]
LinkedIn: / evergrowth-biohealthcare-capital
Phone: +1(704) 957-7746
▶ CONNECT WITH DR. HARVEY TRAN:
Twitter: / drtranbiosci
LinkedIn: / drharveytran
Email: [email protected]
Disclaimer: As a medical doctor/market expert, I’m not a registered investment advisor. Despite that I strive to provide the most accurate information, I neither guarantee the accuracy nor timeliness. Past performance does NOT guarantee future results. I reserve the right to make any investment decision for myself and my affiliates pertaining to any security without notification except where it is required by law. I am also NOT responsible for the actions of my affiliates. The thesis that I presented may change anytime due to the changing nature of information itself. Investment in stocks and options can result in a loss of capital. The information presented should NOT be construed as a recommendation to buy or sell any form of security. My articles and videos are best utilized as educational and informational materials to assist investors in your own due diligence process. That said, you are expected to perform your own due diligence and take responsibility for your actions. You should also consult with your own financial advisor for specific guidance, as financial circumstances are individualized. That aside, what I shared with you is not professional medical advice. I simply share with you what I share with my own family to help get more out of your life.